Pfizer (PFE) Scores Legal And Product Wins, Is The Stock Now Too Expensive?
Pfizer (PFE) Scores Legal And Product Wins, Is The Stock Now Too Expensive? Simply Wall St
Covered in this story
Analyst targets on Pfizer
- Cantor Fitzgerald: $28.3 → $28 by Oct 2027 · Neutral via TIKR.com
- Bank of America: $28.3 → $29 by Oct 2027 · Neutral via TIKR.com
- JPMorgan: $28.3 → $30 by Oct 2027 · Neutral via The Globe and Mail
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $PFE yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Pfizer →Dalsna Finance is currently tracking 50 stories mentioning Pfizer, the earliest published 18 Jun 2026.
Summary aggregated from Simply Wall St's public RSS feed. The full reporting belongs to Simply Wall St — please read it on their site.